Plus   Neg

Nektar Therapeutics (NKTR) Climbed To A New High On Study Results

Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) announced positive results from their Phase 1/2 study of the combination of Opdivo with Nektar's NKTR-214 on Saturday.

Nektar Therapeutics gapped open sharply higher Monday, but pared its gains during the first half of the session. Shares still finished with a gain of 4.60 at $37.10 on the highest volume of the year. The stock rose to its fifth consecutive new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT